Neoleukin Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Donna Cochener-Metcalfe
Chief executive officer
US$993.9k
Total compensation
| CEO salary percentage | 29.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | no data |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Jul 18
Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Situation
Mar 10We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Nov 19Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?
Jun 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$994k | US$291k | -US$58m |
Compensation vs Market: Donna's total compensation ($USD993.90K) is above average for companies of similar size in the US market ($USD733.09K).
Compensation vs Earnings: Insufficient data to compare Donna's compensation with company performance.
CEO
Donna Cochener-Metcalfe (48 yo)
less than a year
Tenure
US$993,899
Compensation
Ms. Donna M. Cochener-Metcalfe, J.D., served as General Counsel and Senior Vice President of Legal at Neoleukin Therapeutics, Inc since March 2022 until March 31, 2023 and serves as its Interim Chief Execu...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman | 9.9yrs | US$206.25k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$143.58k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$320.29k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$132.25k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$142.25k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.25k | no data |
4.0yrs
Average Tenure
56yo
Average Age
Experienced Board: NLTX's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/20 16:41 |
| End of Day Share Price | 2023/12/18 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neoleukin Therapeutics, Inc. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Gregory Harrison | BofA Global Research |
| Corey Davis | Canaccord Genuity |